TD Cowen Reiterates Buy Rating for Kura Oncology (NASDAQ:KURA)

TD Cowen reiterated their buy rating on shares of Kura Oncology (NASDAQ:KURA) in a report issued on Thursday,Benzinga reports.

A number of other equities analysts also recently weighed in on the stock. UBS Group started coverage on shares of Kura Oncology in a research note on Thursday, October 24th. They set a “buy” rating and a $27.00 price target on the stock. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Kura Oncology in a research report on Thursday. StockNews.com downgraded Kura Oncology from a “hold” rating to a “sell” rating in a research report on Wednesday, November 20th. Wedbush reaffirmed an “outperform” rating and issued a $37.00 price objective on shares of Kura Oncology in a research note on Monday, November 4th. Finally, Lifesci Capital upgraded Kura Oncology to a “strong-buy” rating in a report on Tuesday, October 22nd. One research analyst has rated the stock with a sell rating, one has given a hold rating, nine have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, Kura Oncology currently has a consensus rating of “Moderate Buy” and a consensus price target of $29.38.

Kura Oncology Trading Up 7.4 %

Shares of KURA stock opened at $10.80 on Thursday. The firm’s 50-day simple moving average is $17.88 and its 200-day simple moving average is $19.67. The company has a debt-to-equity ratio of 0.02, a current ratio of 11.47 and a quick ratio of 11.47. Kura Oncology has a 1-year low of $9.06 and a 1-year high of $24.17. The firm has a market cap of $839.81 million, a P/E ratio of -4.58 and a beta of 0.86.

Institutional Investors Weigh In On Kura Oncology

Several hedge funds have recently modified their holdings of KURA. nVerses Capital LLC acquired a new position in Kura Oncology in the 3rd quarter worth $25,000. ProShare Advisors LLC increased its position in shares of Kura Oncology by 9.7% during the first quarter. ProShare Advisors LLC now owns 18,014 shares of the company’s stock worth $384,000 after acquiring an additional 1,588 shares during the last quarter. Aaron Wealth Advisors LLC increased its position in shares of Kura Oncology by 2.4% during the second quarter. Aaron Wealth Advisors LLC now owns 70,148 shares of the company’s stock worth $1,444,000 after acquiring an additional 1,673 shares during the last quarter. The Manufacturers Life Insurance Company lifted its stake in shares of Kura Oncology by 5.4% in the second quarter. The Manufacturers Life Insurance Company now owns 38,536 shares of the company’s stock worth $793,000 after acquiring an additional 1,976 shares in the last quarter. Finally, Hsbc Holdings PLC boosted its holdings in Kura Oncology by 13.4% in the second quarter. Hsbc Holdings PLC now owns 18,300 shares of the company’s stock valued at $374,000 after purchasing an additional 2,167 shares during the last quarter.

About Kura Oncology

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.